Trial Profile
An Open Label, Prospective, Multi-Center Trial on the Effect of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) on Inflammatory and Fibrous Lesions in Patients with Intestinal Crohn's Diesease. ACTIF Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Acronyms ACTIF
- 04 Feb 2011 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 30 Dec 2010 New trial record